In contrast, many antitumor vaccines investigated for patients with melanoma, a disease characterized by many more tumor-infiltrating CD8+ lymphocytes, have failed to demonstrate significant clinical benefit to mCRPC patients. The gene discussed is CD8A; the disease is neoplasm.